Fonasterin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fonasterin

Quick Facts

Property Description
Active Ingredient Finasteride
Form Film-coated tablets (Oral)
Pharmacological Class 5alpha-Reductase Inhibitor
Common Use Modulating androgen-dependent processes
Origin Synthetic compound

What Type of Medicine is Fonasterin?

Fonasterin is a prescription-only, synthetic medication classified pharmacologically as a 5alpha-Reductase Inhibitor. The active ingredient, Finasteride, is a synthetic 4-azasteroid compound. The medicine is manufactured as an oral formulation in the form of film-coated tablets, designed for systemic delivery upon ingestion.

This medication is clinically recognized for its high selectivity and targeted action. The formulation of Fonasterin, based on Finasteride as the sole active agent, positions it as a dedicated single-ingredient therapy. This is crucial as its synthetic origin and standardized oral form ensure verifiable purity and consistent systemic delivery, unlike less standardized agents. Finasteride is a potent and specific 5alpha-reductase inhibitor. This classification means the medicine works by directly interfering with a key enzyme in the body's hormonal system.

Finasteride: Composition and Mechanism Group

The active ingredient in Fonasterin is Finasteride, which functions as a competitive and specific inhibitor of the Type II 5alpha-reductase enzyme. This enzyme is located within the cells of target tissues and is responsible for a critical hormonal conversion pathway.

Specifically, Finasteride blocks the 5alpha-reductase enzyme from converting the hormone Testosterone into the more biologically potent Dihydrotestosterone (DHT). This mechanism, based on enzyme inhibition, is highly selective for the Type II isoenzyme. The drug works to rapidly and sustainably reduce serum and tissue DHT concentrations. The drug acts by lowering the body's levels of the Dihydrotestosterone hormone.

General Purpose of 5alpha-Reductase Inhibition

The general purpose of using Fonasterin is to modulate biological processes that are driven or influenced by Dihydrotestosterone (DHT) by reducing its systemic and tissue levels. This targeted hormonal control provides the basis for its therapeutic application.

The drug is typically used to manage conditions in adult males where the excessive influence or accumulation of Dihydrotestosterone is the underlying physiological mechanism. By interfering with the DHT generation pathway, the drug provides foundational relief or stabilization, addressing the root biological cause rather than merely managing symptoms. The overall benefit is derived from this specific capability to reduce the concentration of the primary hormonal mediator.

Regulatory References

  1. Finasteride Drug Summary (NIH MedlinePlus)
  2. Mechanism of 5-alpha Reductase Inhibitors (NCBI Bookshelf)

What side effects are possible with Fonasterin?

Possible Side Effects and Safety Information

The safety profile for Fonasterin (Finasteride) is defined by official classifications of adverse reactions, which are grouped by frequency and the body system affected, as established by government regulatory authorities.

Sexual dysfunction is the most commonly classified group of adverse reactions, which are often reported to occur early in the course of treatment. These effects are categorized as Common in regulatory documents and include decreased libido, erectile dysfunction, and ejaculation disorders. Less frequent effects are classified as Uncommon and may involve breast tenderness, breast enlargement (gynecomastia), and rash. Reports of depression are also documented.

Serious Safety Considerations

Post-marketing surveillance and long-term studies have documented serious safety concerns. These include reports of Male Breast Cancer and an observed increase in the incidence of High-Grade Prostate Cancer (Gleason score 8–10) in clinical trials involving a higher dose of the active ingredient. Additionally, spontaneous reports classify events such as Suicidal Ideation, anxiety, and persistent forms of sexual dysfunction (continuing after discontinuation of the medicine) in the Not Known frequency category.

Safety Constraints and Special Populations

Official labeling includes specific constraints, such as the medication’s known interference with Prostate Specific Antigen (PSA) blood test results, which must be accounted for in patient monitoring. Fonasterin is strictly contraindicated in women who are pregnant or may become pregnant due to the risk of external genital abnormalities in a male fetus. Caution is advised in patients with pre-existing hepatic impairment due to the drug's metabolism.

Overdose and Emergency Response

Overdose and When to Seek Help

The official prescribing information for Fonasterin establishes a highly constrained profile regarding acute overdose in humans. Regulatory documentation notes that single doses of the active ingredient, Finasteride, administered to healthy subjects at up to 400 mg, as well as chronic daily doses up to 80 mg for three months, were generally well tolerated. These clinical studies documented no specific set of adverse effects or a unique toxicity syndrome directly attributable to this high exposure, establishing a high threshold for acute toxicity in controlled settings.

Despite the clinical observations of high-dose tolerability, it is an officially mandated requirement to seek immediate medical attention for any suspected overdose. The basis for this regulatory instruction is that no specific antidote is known for Fonasterin. Furthermore, no specific treatment is officially recommended in the event of an overdose.

Consequently, the guidance for managing a Fonasterin overdose is limited to general measures that are symptomatic and supportive. All instances of ingestion beyond the prescribed amount must be evaluated by a healthcare professional. Prompt contact with emergency services or a poison control center is necessary to ensure appropriate medical observation and the delivery of supportive care.

Therapeutic Uses of Fonasterin

What Fonasterin Treats: Main Uses and Benefits

Fonasterin may be part of symptomatic management for men experiencing symptoms related to functional stress associated with Benign Prostatic Hyperplasia (BPH), or an enlarged prostate. It is used to help address the cluster of Lower Urinary Tract Symptoms (LUTS), such as difficulty starting to urinate, a weak stream, and the frequent need to use the restroom, especially at night. The medication is commonly utilized to assist with these symptoms. The primary therapeutic domains where the medication is relevant involve supporting symptom management in conditions associated with BPH and Androgenetic Alopecia (male-pattern hair loss).

This generally contributes to easing the overall symptom load and is particularly relevant in clinical settings marked by increased discomfort or tension, applied across domains where additional symptomatic support is needed. This medication supports symptomatic relief that may help patients cope more steadily with difficult episodes. For hair loss, the medication is commonly used to help with symptoms related to hereditary hair thinning and is applied in clinical settings that involve acute or unstable symptom patterns, relevant for easing symptoms related to hair loss that typically manifest on the scalp's crown and anterior mid-scalp area.

Quick Fact: Symptomatic Support in LUTS
Symptom Category Obstructive and Irritative Urinary Symptoms
Typical Context Chronic BPH management
Patient Benefit Assists with maintaining functional stability

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Fonasterin is officially indicated for use exclusively in adult men. Use is contraindicated in two absolute populations: females who are or may potentially be pregnant, and individuals with a known hypersensitivity to the active ingredient, Finasteride, or any formulation components.

The medicine is not indicated for pediatric use, as safety and effectiveness have not been established in children and adolescents under 18 years of age. Older men (geriatric patients) are eligible for use, and regulatory documentation confirms that no dosage adjustment is necessary for this age group or for patients with renal impairment.

Caution is advised for patients with existing liver function abnormalities (hepatic impairment) because the drug is metabolized in the liver and formal pharmacokinetic studies in this population are lacking. An excipient restriction means that individuals with rare hereditary disorders such as total lactase deficiency should not use this medicine.

Pregnancy and Lactation Eligibility Status: Fonasterin is contraindicated in pregnancy. Women who are pregnant or may potentially be pregnant must not handle crushed or broken tablets due to the risk of absorption and potential harm to a male fetus. The medicine is not indicated for women, making lactation eligibility irrelevant.


Connection to the overall eligibility profile: Governmental regulatory documents strictly define the eligible user population as adult men without a known hypersensitivity or specific excipient intolerance. Non-eligibility is explicitly established via contraindications for pregnant women and statements that the drug is not indicated for use in children.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fonasterin (Finasteride) has been shown to have a low risk of clinically significant drug-drug interactions, according to official regulatory evaluations. Studies involving co-administration with commonly used compounds, including antipyrine, digoxin, propranolol, theophylline, and warfarin, did not result in clinically meaningful interactions.


Pharmacokinetic and Exposure Considerations

Finasteride is primarily metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Although Finasteride does not significantly affect this enzyme system itself, substances that inhibit or induce CYP3A4 may alter its plasma concentration:

  • CYP3A4 Inhibitors would likely increase Fonasterin's systemic exposure by reducing its clearance.
  • CYP3A4 Inducers would likely decrease Fonasterin's systemic exposure. The herbal product St John's Wort (Hypericum perforatum) is noted as a potential CYP3A4 inducer.

Interaction-Related Restrictions and Cautions

Category Regulatory Statement
Co-Class Restriction Co-administration of Fonasterin with other 5alpha-reductase inhibitors is advised against.
Food and Alcohol Fonasterin may be taken with or without food. No clinically significant interaction with alcohol is documented.
Population-Specific Caution Patients with hepatic insufficiency (liver disease) may experience a slower elimination rate, which could lead to increased systemic exposure.

Mechanism of Action

Selective Blockade of 5alpha-Reductase Type II

Fonasterin acts as a competitive and selective inhibitor of the enzyme 5alpha-Reductase Type II (SRD5A2), which is highly concentrated in androgen-sensitive tissues, such as the prostate and scalp. This molecular action directly and rapidly blocks the enzyme from catalyzing the conversion of Testosterone into the more potent androgen, Dihydrotestosterone (DHT). This initiates the entire cascade by limiting the supply of the most active hormonal mediator in that pathway.

Reductio in Androgen Potency

By preventing this conversion, Fonasterin leads to a verifiable reduction in Dihydrotestosterone (DHT) concentration both systemically (approximately 70%) and locally (over 90% in target tissues). Since DHT is a potent mediator of cell growth and activity, the physiological consequence of this sustained reduction is the cessation of the proliferative hormonal signal. This change in the hormonal environment leads to the gradual regression and reduction in the volume of DHT-dependent tissue.

Time-Dependent Tissue Remodeling

While the enzyme inhibition is rapid, the observable physiological effects rely on the subsequent time-dependent process of cellular adjustment and remodeling. This requires continuous blockade of the enzyme over weeks to months for the target tissues to fully respond to the reduced hormonal stimulus. The mechanism, therefore, imposes a hormonally limited state within the androgen-dependent tissues, contrasting with immediate pharmacological responses.

Dosage and Administration Information

How to Use Fonasterin

Fonasterin is an oral medication supplied as a film-coated tablet for systemic administration. Standard usage involves precise administration procedures and dosing schedules that are independent of mealtimes. The tablet must be swallowed whole and is specifically labeled with the instruction to not crush, break, or chew.

Administration is generally consistent across both approved uses, requiring the tablet to be taken once daily (qDay). It is recommended that the daily dose be taken at approximately the same time each day.


Official Dosing Regimens

Dosing is dependent on the clinical context for which the medicine is used:

Context Standard Adult Daily Dose Frequency Duration Pattern
Benign Prostatic Hyperplasia (BPH) 5 mg tablet Once Daily Typically long-term; effects assessed after 6 months
Androgenetic Alopecia (Hair Loss) 1 mg tablet Once Daily Typically long-term; requires 3+ months for observation of benefit

Administration and Procedural Rules

The medicine may be taken with or without food. If a dose is missed, the standard procedure is to avoid taking a double dose to compensate; the individual should omit the missed dose and resume the regular once-daily schedule.

Dose Adjustment for Specific Groups: No routine dosage adjustment is required for older adults or for patients diagnosed with renal impairment. The medicine is not indicated for use in individuals under 18 years of age.

Recent Clinical Evidence

Fonasterin: Recent Clinical Evidence


A. Core Mechanism and Efficacy Research

Research has explored whether Fonasterin may influence biological markers implicated in benign prostatic hyperplasia (BPH) and male pattern hair loss. A pooled analysis of randomized controlled trials (RCTs) examining treatment for BPH, primarily with the 5 mg dose, found a measurable change in prostatic volume and flow rates compared to placebo. Similarly, studies focusing on male pattern hair loss (primarily with the 1 mg dose) were associated with measurable changes in hair count and investigator assessments over one to two years.

B. Long-Term Data and Tolerability

Long-term open-label extension studies were conducted to assess the drug's use and tolerability profile over time. Tolerability data was collected and analyzed as part of these studies. Research protocols documented participant characteristics and exclusion criteria, such as those with pre-existing clinically significant kidney issues. Data was also collected to assess long-term patient adherence to the treatment regimens examined.

C. Research into Combination and Novel Formulations

Separate pilot studies have examined Fonasterin's use in combination with other standard-of-care treatments for BPH. The combination was studied to assess whether it affected measured outcomes like urinary symptom scores. Additionally, research is ongoing to evaluate novel formulations, such as topical applications, which aim to study efficacy while examining whether they affect systemic exposure or serum hormone levels differently than oral administration. The outcomes support the basis for further investigation into these new delivery methods.

Key Studies & References

  1. Finasteride in the Treatment of Men With Androgenetic Alopecia: A Randomized, Controlled Trial
  2. Clinical Assessment of a Novel Topical Fonasterin Formulation for Androgenetic Alopecia: A Phase II Study

Frequently Asked Questions (FAQ)

Common questions about Fonasterin (FAQ)


Q: How quickly should I expect to see an effect from Fonasterin?

A: Official information indicates that the therapeutic effect of Fonasterin relies on consistent, continuous use. Because the medicine works by gradually altering hormone-driven processes, visible effects are not immediate. For hair loss, three months or more of daily use is generally necessary before a benefit is noted, and for BPH, effects are typically assessed after six months of consistent treatment.


Q: How long does the effect of a dose of Fonasterin last?

A: The half-life of the active ingredient is approximately 4.7 to 8 hours in men, which is the time it takes for half of the medicine to be eliminated from the body. Although the drug is cleared from the system within a couple of days, regulatory information states that maintaining the therapeutic reduction in Dihydrotestosterone (DHT) levels requires continuous administration.


Q: What happens if I forget a dose of Fonasterin?

A: If a dose is forgotten, official administration instructions advise against taking a double dose to compensate. The official instructions advise that the missed dose should be omitted entirely, and individuals should resume the regular once-daily schedule with the next scheduled dose.


Q: How does Fonasterin relate to the body's natural processes?

A: Fonasterin is classified as a medicine that acts on the body's hormonal system. It works by selectively blocking the Type II 5alpha-Reductase enzyme, which is responsible for converting the hormone Testosterone into Dihydrotestosterone (DHT). By blocking this conversion, Fonasterin lowers the body's concentration of DHT.


Q: Can Fonasterin cause long-term side effects?

A: Post-marketing reports described in official regulatory documents include instances of adverse reactions that were reported to persist after discontinuation of the medicine. These include reports of persistent sexual dysfunction, anxiety, depression, and suicidal ideation, which are classified as having a 'Frequency Not Known'.


Q: Is it normal to feel a bit nauseous when starting Fonasterin?

A: Nausea is not classified among the most frequently reported side effects in the core clinical data. However, some general adverse event lists from governmental sources have noted reports of nausea in the gastrointestinal system as an effect reported at an unspecified frequency.


Q: What are common user experiences reported with Fonasterin's side effects?

A: In clinical trials, sexual dysfunction was among the most commonly reported groups of adverse reactions. These effects, which include decreased libido, erectile dysfunction, and ejaculation disorders, are classified as 'Common' (reported in 1% to 10% of patients) and were often reported to occur early in the course of treatment.


Q: Why is it important to keep taking Fonasterin even if I feel better?

A: The biological basis of the medicine’s action requires continuous blockade of the DHT-producing enzyme to maintain the therapeutic effect. Official documents note that discontinuing treatment leads to the gradual reversal of the drug's beneficial effects, typically within 12 months.


Q: How soon after stopping Fonasterin does it leave the body?

A: The half-life of the active ingredient is approximately 4.7 to 8 hours in men, which describes the time needed for half the dose to be eliminated. For most patients, this means that the majority of the drug is eliminated from the systemic circulation within a few days after the last dose.


Q: What is the main difference between Fonasterin and similar drugs?

A: Fonasterin is classified as a 5alpha-reductase inhibitor. This drug class is defined by its specific action of blocking the enzyme that converts Testosterone to Dihydrotestosterone (DHT). This targeted action forms the basis for its authorized uses.


Q: Is Fonasterin available over the counter?

A: No, Fonasterin is regulated as a prescription-only medicine. Official labeling specifies that Fonasterin is a prescription-only medicine, meaning it is not available for purchase over the counter.


Q: Does Fonasterin treat other conditions besides the main one?

A: According to official regulatory indications, Fonasterin is authorized for the treatment of symptomatic Benign Prostatic Hyperplasia (BPH) and for male pattern hair loss (androgenetic alopecia). These are the conditions listed in the official regulatory indications.


Q: How long has Fonasterin been approved for use?

A: The active ingredient in Fonasterin, Finasteride, was first approved by the FDA in 1992 for the treatment of BPH. It was subsequently approved in 1997 for the treatment of male pattern hair loss.


Q: What are the most common reasons someone might stop taking Fonasterin?

A: Clinical trial data indicates that the most common reasons for participants discontinuing the medicine were adverse reactions related to sexual function. These generally include events such as decreased libido, erectile dysfunction, or ejaculation disorders.


Q: Is Fonasterin known to cause weight gain or loss?

A: While official documents list edema (swelling) as a reported side effect, weight gain or loss is not listed among the common side effects. General adverse event reports to government agencies have included instances of 'unusual weight gain or loss'.


Q: Is the research on Fonasterin ongoing?

A: Yes, research and safety monitoring of the medicine are ongoing. Regulatory authorities continue to periodically review long-term safety data, and studies are being conducted to evaluate novel formulations, such as topical applications.


Q: Does Fonasterin affect mood or sleep?

A: Official regulatory documents list reports of depression and anxiety as adverse reactions reported by some users. Somnolence, which is unusual drowsiness or sleepiness, has also been documented in clinical studies.


Q: What is the risk of dependence or addiction with Fonasterin?

A: The active ingredient in Fonasterin is not classified as a controlled substance by regulatory bodies. Official drug information does not contain any warnings indicating a risk of dependence or addiction associated with its use.


Q: Are generic versions of Fonasterin the same as the brand name?

A: Generic versions of the medicine contain the same active ingredient, Finasteride. Generic products are evaluated by regulatory authorities and must meet the same standards for quality, strength, and performance as the brand name product.


Q: Can Fonasterin cause skin sensitivity or rash?

A: Yes, official safety data lists rash as an Uncommon adverse reaction. Other skin-related reactions that have been reported include urticaria (hives) and pruritus (itching).


Q: Is Fonasterin widely used internationally?

A: The active ingredient, Finasteride, is approved, used, and monitored by multiple major international regulatory bodies. This includes drug agencies in Europe, Canada, and Australia, among others.


Q: Does Fonasterin impact fertility?

A: Post-marketing reports to regulatory agencies have included instances of male infertility and poor seminal quality. These reports also noted that semen quality was reported to return to normal after discontinuation of the medicine in some cases.


Q: What does 'off-label use' mean for Fonasterin?

A: Off-label use refers to the use of a medicine for any purpose, patient group, or dosage that has not been specifically evaluated and approved by the official regulatory body. The official label strictly defines the authorized uses.


Q: What happens if I take more Fonasterin than directed?

A: In clinical trials, patients received doses significantly higher than the standard without adverse effects. Official documents state that the daily dose should not be exceeded. No specific treatment for an overdose is currently recommended.


Q: Can Fonasterin be used alongside herbal remedies?

A: Regulatory documents state that Fonasterin is primarily metabolized by the CYP3A4 enzyme system. The herbal product St John's Wort (Hypericum perforatum) is noted as a potential inducer of this system, which could potentially decrease the concentration of Fonasterin.


Q: How often do the side effects of Fonasterin occur?

A: Side effects are classified by their estimated frequency based on clinical trials and post-marketing data. 'Common' effects are those reported in 1% to 10% of patients, while 'Uncommon' effects occur in less than 1%. Other events are classified as 'Rare' or 'Frequency Not Known'.


Q: What is the risk of interactions with common pain relievers?

A: Official regulatory evaluations indicate a low risk of clinically significant drug-drug interactions. Co-administration studies with several common compounds did not result in clinically meaningful interactions. However, official documents note that caution has been advised when combining with certain drug classes, such as NSAIDs, in the presence of compromised renal function.


Q: Does Fonasterin have an effect on kidney function?

A: The drug label states that no routine dosage adjustment is necessary for patients with renal impairment. Studies show that even with decreased urinary excretion of metabolites, the body compensates by increasing excretion through the feces.


Q: Is Fonasterin effective for everyone who uses it?

A: Clinical trial evidence indicates that measurable changes were observed in a percentage of patients. However, the official studies also show that not all participants demonstrated a benefit, suggesting variable outcomes among individuals.


Q: Are there different strengths of Fonasterin available?

A: Yes, Fonasterin is officially available in two authorized strengths. The 5 mg tablets are indicated for BPH treatment, and the 1 mg tablets are indicated for the treatment of androgenetic alopecia.


Q: Does Fonasterin affect the way my other daily medicines work?

A: Official regulatory evaluations have concluded that Fonasterin has a low risk of clinically significant drug-drug interactions. The drug does not appear to significantly interfere with the CYP450 enzyme system, which is responsible for metabolizing many common medications.

How should Fonasterin be stored and disposed of?

The official regulatory documents for the structurally similar drug, Finasteride, specify conditions for storage, handling, and disposal.

Scope Official Requirement
Storage Conditions Does not require any special storage conditions.
Handling Requirement Pregnant women should not handle crushed or broken tablets due to the risk to a male fetus. The tablet's film-coating prevents contact with the active substance during normal handling.
Disposal Instructions Any unused product or waste material must be disposed of in accordance with local regulatory requirements.
Packaging Rule Keep the medicine in its original container.

Official Storage and Disposal Summary

The regulatory profile for the product is defined by two primary elements: a general condition of no special storage requirements and a strict handling constraint. The handling rule mandates that the protective film coating of the tablet must be preserved, and pregnant individuals must avoid contact with the active substance due to potential teratogenic effects. Final disposal of unused or expired material must adhere to the local waste management regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fonasterin found in:

A-Z Index: